Ruxolitinib for the prevention of thrombosis in polycythemia vera: a systematic review and meta-analysis.
Journal
Blood advances
ISSN: 2473-9537
Titre abrégé: Blood Adv
Pays: United States
ID NLM: 101698425
Informations de publication
Date de publication:
28 Jan 2020
28 Jan 2020
Historique:
received:
28
10
2019
accepted:
27
11
2019
entrez:
28
1
2020
pubmed:
28
1
2020
medline:
21
7
2020
Statut:
ppublish
Résumé
Ruxolitinib is a recommended second-line treatment for the prevention of thrombosis in patients with polycythemia vera who become resistant or intolerant to hydroxyurea; however, evidence regarding its efficacy in terms of thrombosis reduction is uncertain. We searched Medline, Embase, and archives of abstracts from the European Hematology Association and the American Society of Hematology annual congresses from 2014 onward for randomized controlled trials comparing the treatment vs best available therapy (BAT). Our search retrieved 80 records; after screening of abstracts and full text, the total was reduced to 16. Evidence came from 4 randomized controlled trials, including 663 patients (1057 patients per year). We estimated a thrombosis risk ratio of 0.56 for ruxolitinib BAT, corresponding to an incidence of 3.09% and 5.51% patients per year, respectively. The number of thrombotic events reported with ruxolitinib was consistently lower than that with BAT in our sample, but, globally, the difference did not reach significance (P = .098). Hard evidence in favor of ruxolitinib is lacking; a clinical trial on selected patients at high risk of thrombosis would be warranted, but its feasibility is questionable.
Identifiants
pubmed: 31985808
pii: S2473-9529(20)31667-0
doi: 10.1182/bloodadvances.2019001158
pmc: PMC6988397
doi:
Substances chimiques
Nitriles
0
Pyrazoles
0
Pyrimidines
0
ruxolitinib
82S8X8XX8H
Types de publication
Journal Article
Meta-Analysis
Systematic Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
380-386Informations de copyright
© 2020 by The American Society of Hematology.
Références
Blood. 2017 Oct 26;130(17):1889-1897
pubmed: 29074595
Blood. 2012 Feb 9;119(6):1363-9
pubmed: 22160617
Leukemia. 2018 May;32(5):1057-1069
pubmed: 29515238
Blood. 2019 Jul 25;134(4):341-352
pubmed: 31151982
Ann Hematol. 2018 Sep;97(9):1591-1600
pubmed: 29804268
N Engl J Med. 2013 Jan 3;368(1):22-33
pubmed: 23216616
Semin Hematol. 1997 Jan;34(1):17-23
pubmed: 9025158
Blood Coagul Fibrinolysis. 2016 Sep;27(6):648-52
pubmed: 26569516
Ann Hematol. 2018 Apr;97(4):617-627
pubmed: 29396713
N Engl J Med. 2015 Jan 29;372(5):426-35
pubmed: 25629741
Am J Hematol. 2017 Nov;92(11):1131-1136
pubmed: 28699191
Lancet Oncol. 2017 Jan;18(1):88-99
pubmed: 27916398
Br J Haematol. 2017 Jan;176(1):76-85
pubmed: 27858987
Syst Rev. 2016 Dec 5;5(1):210
pubmed: 27919275
Haematologica. 2016 Jul;101(7):821-9
pubmed: 27102499
Haematologica. 2019 Dec;104(12):2391-2399
pubmed: 31123026